Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

T-VEC and checkpoint therapy for melanoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.06.17
Views: 2517

Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA

Prof Andtbacka speaks with ecancer at ASCO 2017 about results from the '264 study, the first such investigation combining the oncolytic virus T-VEC with checkpoint inhibition to treat melanoma.

He describes a response rate of 38% among the 98 patients receiving T-VEC and ipilimumab, with overall survival data yet to mature. 

Adverse events associated with T-VEC compared to ipilimumab monotherapy as a control include a higher rate of fatigue and chills, with 28% of patients have a grade ≥3 adverse event compared to 18%.

Prof Andtbacka goes on to outline further possible combinations for T-VEC based on the tolerability response rates of this trial, including use of a PD-1 antibody.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

ONJ e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation